Literature DB >> 12435580

Anthrax toxin: a tripartite lethal combination.

Paolo Ascenzi1, Paolo Visca, Giuseppe Ippolito, Andrea Spallarossa, Martino Bolognesi, Cesare Montecucco.   

Abstract

Anthrax is a severe bacterial infection that occurs when Bacillus anthracis spores gain access into the body and germinate in macrophages, causing septicemia and toxemia. Anthrax toxin is a binary A-B toxin composed of protective antigen (PA), lethal factor (LF), and edema factor (EF). PA mediates the entry of either LF or EF into the cytosol of host cells. LF is a zinc metalloprotease that inactivates mitogen-activated protein kinase kinase inducing cell death, and EF is an adenylyl cyclase impairing host defences. Inhibitors targeting different steps of toxin activity have recently been developed. Anthrax toxin has also been exploited as a therapeutic agent against cancer.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12435580     DOI: 10.1016/s0014-5793(02)03609-8

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  46 in total

1.  Protection against anthrax toxemia by hexa-D-arginine in vitro and in vivo.

Authors:  Miroslav S Sarac; Juan R Peinado; Stephen H Leppla; Iris Lindberg
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

2.  Inhibition of anthrax lethal factor: lability of hydroxamate as a chelating group.

Authors:  Feng Li; Irina Chvyrkova; Simon Terzyan; Nancy Wakeham; Robert Turner; Arun K Ghosh; Xuejun C Zhang; Jordan Tang
Journal:  Appl Microbiol Biotechnol       Date:  2012-01-25       Impact factor: 4.813

3.  Enhancing molecular flux through nanopores by means of attractive interactions.

Authors:  John J Kasianowicz; Tam L Nguyen; Vincent M Stanford
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-25       Impact factor: 11.205

4.  Dynamics and energetics: a consensus analysis of the impact of calcium on EF-CaM protein complex.

Authors:  Elodie Laine; Arnaud Blondel; Thérèse E Malliavin
Journal:  Biophys J       Date:  2009-02-18       Impact factor: 4.033

5.  Thioamide hydroxypyrothiones supersede amide hydroxypyrothiones in potency against anthrax lethal factor.

Authors:  Arpita Agrawal; César Augusto F de Oliveira; Yuhui Cheng; Jennifer A Jacobsen; J Andrew McCammon; Seth M Cohen
Journal:  J Med Chem       Date:  2009-02-26       Impact factor: 7.446

6.  Inhibition of Interleukin 1β (IL-1β) Expression by Anthrax Lethal Toxin (LeTx) Is Reversed by Histone Deacetylase 8 (HDAC8) Inhibition in Murine Macrophages.

Authors:  Soon-Duck Ha; Chantelle Reid; Shahab Meshkibaf; Sung Ouk Kim
Journal:  J Biol Chem       Date:  2016-02-24       Impact factor: 5.157

7.  Molecular assembly of lethal factor enzyme and pre-pore heptameric protective antigen in early stage of translocation.

Authors:  Laleh Alisaraie; Isabelle Rouiller
Journal:  J Mol Model       Date:  2015-12-11       Impact factor: 1.810

8.  Plant-based vaccine: mice immunized with chloroplast-derived anthrax protective antigen survive anthrax lethal toxin challenge.

Authors:  Vijay Koya; Mahtab Moayeri; Stephen H Leppla; Henry Daniell
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

Review 9.  Prodrug applications for targeted cancer therapy.

Authors:  Irene Giang; Erin L Boland; Gregory M K Poon
Journal:  AAPS J       Date:  2014-07-09       Impact factor: 4.009

10.  Added benefit of raxibacumab to antibiotic treatment of inhalational anthrax.

Authors:  Thi-Sau Migone; Sally Bolmer; John Zhong; Al Corey; Daphne Vasconcelos; Matthew Buccellato; Gabriel Meister
Journal:  Antimicrob Agents Chemother       Date:  2014-12-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.